Quinoxalines Versus Indolinones as Inhibitors of Restenosis

To the Editor:

We would like to point out several issues related to citations of the scientific literature in an article by Yamasaki et al.1 We would like to emphasize that quinoxalines were the first compounds showing excellent efficacy in inhibiting balloon injury-induced stenosis in pigs and rats. Reference 20 in the article by Yamasaki et al, which describes this study, is not quoted correctly, as it omits most of the authors of this pioneering study. The accurate reference is the second citation in the reference section of this letter.2 The efficacy of a quinoxaline in rats is described in the study by Fishbein et al.3

Reference 25, which cites quinoxalines as being synthesized by Muranaka et al,4 is actually wrong. This reference describes indolinones, the very compounds Yamasaki et al1 describe in their own study. Quinoxalines were first described in the study by Kovalenko,5 which should have been quoted instead of Reference 25, crediting the quinoxalines as selective and potent platelet-derived growth factor receptor (PDGFR) kinase inhibitors.

Alexander Levitzki
Department of Biological Chemistry
The Alexander Silberman Institute of Life Sciences, and
Institute for Advanced Studies
The Hebrew University of Jerusalem

Quinoxalines Versus Indolinones as Inhibitors of Restenosis
Alexander Levitzki

Circ Res. 2001;88:e77
doi: 10.1161/hh1101.092522

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2001 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/88/12/e77